Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, RP China.
Drug Dev Ind Pharm. 2013 Jan;39(1):67-76. doi: 10.3109/03639045.2012.657646. Epub 2012 Feb 17.
The objective of present work was to design and evaluate gliclazide push-pull osmotic pump (PPOP) coated with aqueous colloidal polymer dispersions-Eudragit(®) RL 30D and Eudragit(®) RS 30D. The influence of diacetin, diethyl phthalate (DEP), dibutyl sebacate (DBS) and triethyl citrate (TEC) on the free Eudragit(®) RL 30D and Eudragit(®) RS 30D films as plasticizers on drug release were studied. Among these four plasticizers, diacetin offered the smoothest surface of the cast films, and it displayed greatest water vapor transmission coefficient. Free RL and RS films with diacetin also exhibited greatest erosion compared with the other three plasticizers. On the other hand, TEC, DEP and DBS showed greater water absorption. When compared with CA-coated gliclazide PPOP, Eudragit-coated ones showed a f(2) factor of 71.7, indicating the similarity between the release profile of the two formulations. The prepared Eudragit-coated gliclazide PPOP showed typical Zero-order release characteristics, with R being 0.9953. In the in vivo evaluation, the mean relative oral bioavailability of Eudragit-coated PPOP compared to CA-coated ones was 106.9%, demonstrating good bioequivalence. Both of their in vitro-in vivo correlation (IVIVC) showed linear relationship, with R(2) being 0.9955 (Eudragit-coated PPOP) and 0.9987 (CA-coated PPOP), respectively. These results suggested that PPOP coated with Eudragit(®) RL 30D and RS 30D could overcome drawbacks of organic solution coating and promote the development of PPOP.
本工作旨在设计和评价格列齐特推拉渗透泵(PPOP)包衣,包衣材料为水性胶体聚合物分散体- Eudragit(®)RL 30D 和 Eudragit(®)RS 30D。考察了二乙酰基邻苯二甲酸酯(DEP)、癸二酸二丁酯(DBS)和柠檬酸三乙酯(TEC)对 Eudragit(®)RL 30D 和 Eudragit(®)RS 30D 自由膜的影响。在这四种增塑剂中,二乙酰基邻苯二甲酸酯使铸膜的表面最光滑,水蒸气透过系数最大。与其他三种增塑剂相比,含二乙酰基邻苯二甲酸酯的 RL 和 RS 自由膜的侵蚀性也最大。另一方面,TEC、DEP 和 DBS 显示出更大的吸水性。与 CA 包衣格列齐特 PPOP 相比,Eudragit 包衣的制剂具有更高的 f2 因子(71.7),表明两种制剂的释放曲线具有相似性。所制备的 Eudragit 包衣格列齐特 PPOP 显示出典型的零级释放特征,R 为 0.9953。在体内评价中,与 CA 包衣制剂相比,Eudragit 包衣 PPOP 的平均相对口服生物利用度为 106.9%,表明具有良好的生物等效性。它们的体外-体内相关性(IVIVC)均显示线性关系,R2 分别为 0.9955(Eudragit 包衣 PPOP)和 0.9987(CA 包衣 PPOP)。这些结果表明,Eudragit(®)RL 30D 和 RS 30D 包衣的 PPOP 可以克服有机溶剂包衣的缺点,并促进 PPOP 的发展。